Skip to main content
In stock|Targeted Therapy (Antibody-Drug Conjugate)

Naratuximab Emtansine

Oncology TypeHematologic
Drug Class / MechanismADC
No Image
Description

Naratuximab Emtansine is classified as an ADC, sourced for use within our Targeted Therapy (Antibody-Drug Conjugate) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Antibody-Drug Conjugate)
Oncology TypeHematologic

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3